Julen
Oyarzabal Santamarina
Investigador hasta 2018
Xabier
Aguirre Ena
Profesional Investigador
Publicaciones en las que colabora con Xabier Aguirre Ena (12)
2024
-
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Nature Communications, Vol. 15, Núm. 1
2021
-
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma
Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426
-
Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death
Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications, Vol. 12, Núm. 1
2020
2019
-
Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
Hepatology, Vol. 69, Núm. 2, pp. 587-603
-
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Nature Medicine
2018
-
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces
Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6546-6573
-
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy
Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545
2017
-
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies
Nature Communications, Vol. 8
-
Dual epigenetic modifiers for cancer therapy
Molecular and Cellular Oncology, Vol. 4, Núm. 4
-
Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome
PLoS ONE, Vol. 12, Núm. 12